Summary of the interim report
The “Company” or “Xintela” refers to
Fourth quarter 2023 for the group
Income amounted to TSEK 78 (0).
Loss before tax totalled TSEK 12,175 (loss: 23,384).
Loss per share was
The year 2023 for the group
Income amounted to TSEK 78 (0).
Loss before and tax totalled TSEK 58,367 (loss: 73,165).
Loss per share was
Fourth quarter 2023 for the parent company
Income amounted to TSEK 78 (6,288).
Loss before tax totalled TSEK 9,467 (loss: 7,323).
Loss per share was
The year 2023 for the parent company
Income amounted to TSEK 78 (6,288).
Loss before tax totalled TSEK 39,935 (loss: 39,109).
Loss per share was
At
Significant events in the fourth quarter of 2023
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study. (
First patient dosed in
Significant events after the end of the period
The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.
© Modular Finance, source